DE69327620T2 - Monoklonale Antikörper gegen den epidermalen Wachstumsfaktorrezeptor, Zellen und Verfahren zur ihrer Herstellung und sie erhaltende Zusammensetzungen - Google Patents

Monoklonale Antikörper gegen den epidermalen Wachstumsfaktorrezeptor, Zellen und Verfahren zur ihrer Herstellung und sie erhaltende Zusammensetzungen

Info

Publication number
DE69327620T2
DE69327620T2 DE69327620T DE69327620T DE69327620T2 DE 69327620 T2 DE69327620 T2 DE 69327620T2 DE 69327620 T DE69327620 T DE 69327620T DE 69327620 T DE69327620 T DE 69327620T DE 69327620 T2 DE69327620 T2 DE 69327620T2
Authority
DE
Germany
Prior art keywords
monoclonal antibody
egf
tumor cells
growth factor
inhibiting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69327620T
Other languages
English (en)
Other versions
DE69327620D1 (de
Inventor
Ordonez Alicia Fernandez
De Acosta Del Rio Mateo
Abraham Amparo Emilia Macias
Perez Pedro Pablo Macineira
Bravo Blanca Rosa Tormo
Rodriguez Rolando Perez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IMMUNOLOGIA MOLECULAR CIUDAD D
Original Assignee
IMMUNOLOGIA MOLECULAR CIUDAD D
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CU1992100A external-priority patent/CU22387A1/es
Application filed by IMMUNOLOGIA MOLECULAR CIUDAD D filed Critical IMMUNOLOGIA MOLECULAR CIUDAD D
Publication of DE69327620D1 publication Critical patent/DE69327620D1/de
Application granted granted Critical
Publication of DE69327620T2 publication Critical patent/DE69327620T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE69327620T 1992-08-18 1993-08-18 Monoklonale Antikörper gegen den epidermalen Wachstumsfaktorrezeptor, Zellen und Verfahren zur ihrer Herstellung und sie erhaltende Zusammensetzungen Expired - Lifetime DE69327620T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU1992100A CU22387A1 (es) 1992-08-18 1992-08-18 Anticuerpos monoclonados que reconocen el receptor del factor de crecimiento epidermico. procedimiento de obtencion
CU1993017 1993-03-01

Publications (2)

Publication Number Publication Date
DE69327620D1 DE69327620D1 (de) 2000-02-24
DE69327620T2 true DE69327620T2 (de) 2000-08-03

Family

ID=25746823

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69327620T Expired - Lifetime DE69327620T2 (de) 1992-08-18 1993-08-18 Monoklonale Antikörper gegen den epidermalen Wachstumsfaktorrezeptor, Zellen und Verfahren zur ihrer Herstellung und sie erhaltende Zusammensetzungen

Country Status (7)

Country Link
EP (1) EP0586002B1 (de)
AT (1) ATE188874T1 (de)
DE (1) DE69327620T2 (de)
DK (1) DK0586002T3 (de)
ES (1) ES2144440T3 (de)
GR (1) GR3033290T3 (de)
PT (1) PT586002E (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
ES2166368T3 (es) 1993-12-24 2002-04-16 Merck Patent Gmbh Inmunoconjugados.
US6149921A (en) * 1993-12-29 2000-11-21 Centro De Inmunologia Molecular Vaccine compositions for eliciting an immune response against N-acetylated gangliosides and their use for cancer treatment
CU22420A1 (es) * 1993-12-29 1996-01-31 Centro Inmunologia Molecular Composicion vacunal para el desarrollo de una respuesta contra gangliosidos n glicolilados y su uso para el tratamiento del cancer
GB9405046D0 (en) * 1994-03-15 1994-04-27 Unilever Plc Skin treatment composition
CU22615A1 (es) * 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
ATE208633T1 (de) * 1994-09-16 2001-11-15 Merck Patent Gmbh Immunokonjugate
IT1277827B1 (it) * 1995-03-01 1997-11-12 Ministero Uni Ricerca Scient E Anticorpo monoclonale chimerico murino/umano o un suo frammento specifico per il recettore egf (egf-r)
ATE208403T1 (de) * 1995-05-26 2001-11-15 Merck Patent Gmbh Antiidiotypische antikörper die eine immunantwort gegen den rezeptor für epidermalen wachstumsfaktor induzieren
EP0745612B1 (de) * 1995-05-26 2001-11-07 MERCK PATENT GmbH Antiidiotypische Antikörper die eine Immunantwort gegen den Rezeptor für epidermalen Wachstumsfaktor induzieren
US5942602A (en) * 1997-02-13 1999-08-24 Schering Aktiengessellschaft Growth factor receptor antibodies
US6235883B1 (en) * 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US20020173629A1 (en) 1997-05-05 2002-11-21 Aya Jakobovits Human monoclonal antibodies to epidermal growth factor receptor
CN1239701C (zh) * 2000-05-19 2006-02-01 梨树化学株式会社 抗表皮生长因子受体的人源化抗体
CU22979A1 (es) * 2000-12-08 2004-09-09 Centro Inmunologia Molecular Combinación inmunoterapéutica para el tratamiento de tumores que sobre-expresan receptores con actividad quinasa en residuos de tirosina
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
EP2706116A1 (de) * 2001-01-17 2014-03-12 Emergent Product Development Seattle, LLC Bindungsdomäne-Immunglobulin-Fusionsproteine
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
CU23007A1 (es) * 2001-04-06 2004-12-17 Ct De Inmunologia Molecular Ct De Inmunologia Mole Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
PT2163256E (pt) 2001-05-11 2015-11-20 Ludwig Inst For Cancer Res Ltd Proteínas de ligação específica e suas utilizações
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
JP4298498B2 (ja) * 2001-06-13 2009-07-22 ゲンマブ エー／エス 上皮成長因子受容体（ｅｇｆｒ）に対するヒトモノクローナル抗体
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
DE10355904A1 (de) 2003-11-29 2005-06-30 Merck Patent Gmbh Feste Formen von anti-EGFR-Antikörpern
WO2007014278A2 (en) 2005-07-25 2007-02-01 Trubion Pharmaceuticals, Inc. B-cell reduction using cd37-specific and cd20-specific binding molecules
WO2007146968A2 (en) 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
CN110613845A (zh) 2007-01-25 2019-12-27 达娜-法勃肿瘤研究所公司 抗egfr抗体在治疗egfr突变体介导的疾病中的用途
CA2680854C (en) 2007-03-15 2017-02-14 Ludwig Institute For Cancer Research Treatment method using egfr antibodies and src inhibitors and related formulations
US9283276B2 (en) 2007-08-14 2016-03-15 Ludwig Institute For Cancer Research Ltd. Monoclonal antibody 175 targeting the EGF receptor and derivatives and uses thereof
CN102099377A (zh) 2008-04-11 2011-06-15 新兴产品开发西雅图有限公司 Cd37免疫治疗剂及其与双功能化学治疗剂的联合
AU2010203353B2 (en) 2009-01-12 2016-06-16 Cytomx Therapeutics, Inc Modified antibody compositions, methods of making and using thereof
CU24070B1 (es) * 2011-12-27 2015-01-29 Ct De Inmunología Molecular Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósidos n-glicolilados gm3 (neugcgm3)
EP3086814B1 (de) 2013-12-23 2020-06-24 Bayer Pharma Aktiengesellschaft Binder-konjugate (adcs) mit ksp-inhibitoren
AU2015334886B9 (en) 2014-10-23 2021-07-08 Innate Pharma Treatment of cancers using anti-NKG2A agents
AU2016282723B2 (en) 2015-06-22 2021-09-23 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (ADCs) and antibody prodrug conjugates (APDCs) with enzymatically cleavable groups
CN107921288A (zh) 2015-06-23 2018-04-17 拜耳医药股份有限公司 Ksp抑制剂的靶向缀合物
CA2992375A1 (en) 2015-07-27 2017-02-02 Innocimab Pte Ltd Treatment of patients diagnosed with pancreatic ductal adenocarcinoma using monoclonal antibodies against the epidermal growth factor receptor (egfr)
CN108367004B (zh) 2015-09-21 2022-09-13 阿帕特夫研究和发展有限公司 Cd3结合多肽
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
EP3919518A1 (de) 2016-06-15 2021-12-08 Bayer Pharma Aktiengesellschaft Spezifische antikörper-wirkstoff-konjugate mit ksp-inhibitoren und anti-cd123-antikörpern
CN110072556B (zh) 2016-12-21 2023-05-02 拜耳制药股份公司 具有ksp抑制剂的特异性抗体药物缀合物(adc)
IL310558A (en) 2016-12-21 2024-03-01 Bayer Pharma AG Drug-antibody conjugates with enzymatically cleavable groups
AU2019412489A1 (en) 2018-12-26 2021-06-10 Innate Pharma Leucocyte immunoglobulin-like receptor 2 neutralizing antibodies

Also Published As

Publication number Publication date
EP0586002A2 (de) 1994-03-09
DK0586002T3 (da) 2000-06-19
EP0586002B1 (de) 2000-01-19
ES2144440T3 (es) 2000-06-16
PT586002E (pt) 2000-07-31
EP0586002A3 (en) 1994-05-25
ATE188874T1 (de) 2000-02-15
GR3033290T3 (en) 2000-09-29
DE69327620D1 (de) 2000-02-24

Similar Documents

Publication Publication Date Title
DE69327620T2 (de) Monoklonale Antikörper gegen den epidermalen Wachstumsfaktorrezeptor, Zellen und Verfahren zur ihrer Herstellung und sie erhaltende Zusammensetzungen
JP6181089B2 (ja) 条件依存活性抗上皮細胞増殖因子受容体抗体およびその使用方法
KR101531400B1 (ko) 상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그용도
ES2390826T3 (es) Procedimiento para preparar conjugados de fármaco purificados
JP6282745B2 (ja) 修飾抗上皮成長因子受容体抗体およびその使用法
EP1853322A2 (de) Verfahren zur herstellung von maytansinoid-antikörper-konjugaten
AU2308595A (en) Monoclonal antibodies against hiv-1 and vaccines made thereo f
HUP0101160A2 (hu) Humán szöveti faktor (TF) elleni humanizált antitest és eljárás előállítására
NZ210867A (en) Tumour-specific monoclonal antibodies, production thereof and use
MY137078A (en) Recombinant antibodies associated to gangliosides. their use indiagnosis and treatment of tumors.
KR20190129056A (ko) 항-ly75 항체를 포함하는 약학적 조합물
CN1930187B (zh) 针对表皮生长因子受体的缺失突变体的抗体及其使用
KR20210021489A (ko) 약학적 배합물
EP0213581A2 (de) Monoklonale Antikörper gegen tumorassoziierte Glykoproteine, Verfahren zu ihrer Herstellung sowie ihre Verwendung
WO1996004305A1 (en) Hybrid molecules useful in the treatment of tumors, their preparation and use in pharmaceutical compositions
EA042216B1 (ru) Фармацевтические комбинации, содержащие антитело к ly75
DD295985B5 (de) Anti-Tumorzell-Mittel
MX9705445A (es) Anticuerpos monoclonales anti-cd6 y su usos.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition